Due to the involvement of SHP2 (SH2 domain‐containing protein‐tyrosine phosphatase) in human disease, including Noonan syndrome and cancer, several inhibitors targeting SHP2 have been developed. Here, PTPN11 is linked to Noonan syndrome.